Thu, 27 Nov 2014 18:04:25 GMT
Mon, 24 Nov 2014 16:00:27 GMT
[at noodls] - 24 Nov TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews In multiple industry-related media Dr Glynn Wilson discusses status of clinical programs and advancement ...
Mon, 24 Nov 2014 14:06:00 GMT
[PR Newswire] - SEATTLE, Nov. 24, 2014 /PRNewswire/ -- TapImmune, Inc. (OTCQB: TPIV), is pleased to point its shareholders to the following press articles published recently in which TapImmune CEO Dr Glynn Wilson has ...
Sat, 22 Nov 2014 00:07:33 GMT
Wed, 19 Nov 2014 21:57:03 GMT
Tue, 18 Nov 2014 22:20:07 GMT
[at noodls] - 18 Nov Vaccine & Gene Therapy Institute of Florida to provide expertise in vaccine development and clinical trial design SEATTLE, WASHINGTON, November 18, 2014 - TapImmune, Inc. (OTCQB: TPIV), is pleased ...
Tue, 18 Nov 2014 15:00:00 GMT
[PR Newswire] - SEATTLE, Nov. 18, 2014 /PRNewswire/ --TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a ...
Tue, 18 Nov 2014 13:30:00 GMT
[Marketwired] - TapImmune, Inc. was mentioned positively by analysts reacting to recently published comments by Chairman & CEO Glynn Wilson, Ph.D.
Mon, 10 Nov 2014 22:00:20 GMT
Wed, 05 Nov 2014 14:15:00 GMT
[Accesswire] - New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it ...
Wed, 22 Oct 2014 14:35:40 GMT
[at noodls] - 22 Oct Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox. ... This is an abstract of the ...
Wed, 22 Oct 2014 12:30:00 GMT
[Business Wire] - TapImmune, Inc. , provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
Wed, 15 Oct 2014 16:27:26 GMT
[at noodls] - Tapimmune, a Biotech Company Focused on Stimulating the Body's Own Immune System to Fight Cancer TapImmune, a biotech company focused on stimulating the body's own immune system to fight cancer. Please ...
Tue, 23 Sep 2014 14:47:00 GMT
[Business Wire] - TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.
Thu, 18 Sep 2014 18:30:00 GMT
Thu, 18 Sep 2014 14:30:00 GMT
Thu, 18 Sep 2014 13:00:00 GMT
[Accesswire] - SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate receptor ...
Tue, 16 Sep 2014 12:30:00 GMT
[Business Wire] - TapImmune Inc. is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes.
Mon, 08 Sep 2014 13:05:00 GMT
[Accesswire] - Conference Being Held at Convene Times Square in Midtown NEW YORK / ACCESSWIRE / September 8, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused ...
Thu, 04 Sep 2014 13:00:00 GMT
[Accesswire] - Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (OTCQB: TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday ...